Key Dates

Related Announcements

• October 9, 2020 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).  See NOFO PA 20-272.

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

National Eye Institute (NEI)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

NIAID announces the availability of funds for administrative supplement awards to promote the development of pediatric chemical research models and medical countermeasures (MCM) discovery under the Chemical Countermeasures Research Program (CCRP). There is currently an unmet need in understanding the natural history, pathophysiology, and treatment of critical illness in infants, children, adolescents, and young adults after exposure to highly toxic DHS-designated Chemicals of Concern (CoCs). The administrative supplement funds are intended to support pilot preclinical projects by CCRP-supported researchers that focus on 1) Basic research to elucidate mechanistic differences in susceptibility to CoCs between pediatric and adult populations and/or 2) Applied research towards the discovery and early development of pediatric-safe MCMs.

Background

The CCRP is a NIAID-administered trans-NIH initiative supporting the discovery and early development of MCMs to treat and/or prevent serious morbidities and mortality during and after uncontrolled release of toxic chemicals and materials resulting in highly consequential, mass casualty harm to public health, i.e., a public health chemical emergency. Depending on the substance and route of exposure, the resulting health effects may range from acute to long-term chronic and affect multiple organ systems.

The civilian chemical threat spectrum includes military chemical weapons, toxic industrial chemicals and materials, pharmaceutical-based agents, and others that have been collectively identified by the United States Government (USG) as CoCs. CoCs are highly toxic and MCMs are urgently needed to advance national medical and public health preparedness for, response to, and recovery from, chemical emergencies. MCMs should be easily accessible to first responders and local public health authorities for use in a mass casualty pre-hospital setting or as follow-on treatments in-hospital. MCMs must be safe and effective for the entire population spanning pediatric to adults and the elderly.

In 2010, the National Commission on Children and Disasters Assessment highlighted the lack of disaster readiness for the pediatric population. This is of grave concern considering children are one of the most vulnerable segments of society during disasters and likely to be disproportionately affected by chemical, biological, radiological, nuclear, or explosive agents due to their small size and other physiological differences, such as higher ratio of lung alveolar surface area to body size, differences in metabolic rate and skin permeability. Since children are not small adults, they may require special equipment and care.

Research Objectives

Through this Notice of Special Interest (NOSI), current CCRP awards are eligible to receive supplemental funds to incorporate pediatric relevant chemical MCM research efforts, within the scope of the approved award, that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Examples of relevant research areas include, but are not limited to, development of new pediatric research models and MCM efficacy studies. Applicants must propose research that, if successful, would contribute to a greater understanding of the health, well-being, or medical treatment of the pediatric population during and after a public health emergency involving CoCs.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

• Application Due Date(s) – 6 May 2024; 17 March 2025; 16 March 2026 by 5:00 PM local time of applicant organization.
• For funding consideration, applicants must include “NOT-AI-24-022” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Applicants are strongly encouraged to notify the Program Official listed on the Notice of Award for the parent award that a request has been submitted in response to this NOSI in order to facilitate efficient processing of the request.
   
• Eligibility
  • Active CCRP recipients funded or co-funded by NIAID at the time of application are eligible to apply.
    • Submissions from Research Project Grant (i.e., R01, R21, and R34) recipients will be prioritized over Cooperative Agreement  (i.e., U01, UG3/UH3, U54, and U2C) recipients.
  • Recipients in a no-cost extension are ineligible to apply.
  • Parent awards may not already include funding for pediatric-focused research.
  • This opportunity is not open to SBIR/STTR recipients due to hard budget caps, which do not permit supplement awards that exceed allowable amounts (specific to the different award phases).
     
• Research Strategy
  • The Research Strategy is limited to 6 pages, not including the References Cited.
  • Summarize how the supplemental work relates to and enhances the scope of the parent grant.
  • Describe the supplement’s specific aims, including research design, methods, and data analysis.
  • Clinical Trial is not allowed in response to this NOSI and will be considered nonresponsive.
     
• Budget
  • Application budgets are limited to no more than the amount of the current award or $99,999 direct costs (whichever is lower).
  • The project and budget periods are limited to one year and must be within the currently approved project period of the parent award.
  • For parent awards with large unobligated balances, an explanation and plans for drawdown must be provided.
     
• Administrative Review
  • Each CCRP award-administering IC will administratively review applications submitted to their IC separately and provide programmatic recommendations to the NIAID for award consideration.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: [email protected]     

Houmam Araj, Ph.D.
National Eye Institute (NEI)
Phone: (301) 451-2020
E-mail: [email protected] 

Peter Koch, Ph.D. 
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: (301) 496-0810
E-Mail: [email protected] 

Kiran Vemuri, Ph.D. 
National Institute on Drug Abuse (NIDA)
Phone: (301) 435-4446
Email: [email protected] 

Srikanth Nadadur, Ph.D.
National Institute of Environmental Health Sciences (NIEHS)
Telephone: (984) 287-3296
Email: [email protected] 

Shardell Spriggs, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: (301) 443-8189
Email: [email protected] 

Financial/Grants Management Contact

Tamia Powell
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (240) 669-2982
Email:[email protected]   

Karen Robinson Smith
National Eye Institute (NEI)
Telephone: 301-451-2020
Email: [email protected] 

Sheila Simmons
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: (301) 594-9812
E-mail: [email protected] 

Pamela G. Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: [email protected]

Jenny Greer
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3332
Email: [email protected] 

Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: [email protected]